You searched for: Elicera

Extensive positive media coverage for Elicera in Q3

Elicera reports a solid third quarter with encouraging CARMA data in B-cell lymphoma, including a prolonged complete metabolic response in the...

Elicera co-founder awarded SEK 7,5 million for CAR T-cell research

Springtime for biotech – the thaw has begun

It has sometimes felt discouraging to walk through the biotech sector's wolf winter. A barren capital raising landscape has offered strong headwinds that...

Strong first half of the year for Elicera

Elicera Therapeutics' interim report for the first half of 2025 highlights promising results from the CARMA study, where four out of six patients achieved...

Elicera CEO: “These early results are very encouraging”

Elicera Therapeutics has communicated promising preliminary data from its Phase I/IIa CARMA study with ELC-301, demonstrating complete metabolic response...

Elicera reports strong results in the CARMA study

Elicera continues CARMA study after DSMB approval

Five Nordic biotech stock market winners in H1 2025

The holiday season is upon us, and with 2025 now halfway through, BioStock has taken a closer look at which life science stocks...

Elicera Therapeutics | Global Forum 2025

CEO Jamal El-Mosleh presents Elicera Therapeutics at BioStock Global Forum 2025.

Promising preliminary results for Elicera Therapeutics CAR T-cell study

Preliminary results from the first patient cohort in Elicera Therapeutics' ongoing phase I/IIa trial CARMA with the drug candidate ELC-301 were presented at the 7th...

Towards new milestones – Elicera's plan for 2025 and 2026

Elicera Therapeutics Q1 report highlights promising initial clinical data from the CARMA study with ELC-301, stable patient recruitment and preparations for...

Elicera gets green light to continue CARMA study in B-cell lymphoma

Elicera Therapeutics has received approval from the Data Safety and Monitoring Board (DSMB) to continue its Phase I/IIa trial CARMA, which...